4//SEC Filing
Poulton Stuart 4
Accession 0000950170-25-032309
CIK 0001503802other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 4:51 PM ET
Size
11.5 KB
Accession
0000950170-25-032309
Insider Transaction Report
Form 4
Poulton Stuart
EVP, Chief Development Officer
Transactions
- Award
Stock Option (right to buy)
2025-02-28+10,000→ 10,000 totalExercise: $7.95Exp: 2035-02-27→ Common Stock (10,000 underlying) - Award
Stock Option (right to buy)
2025-02-28+9,166→ 9,166 totalExercise: $7.95Exp: 2035-02-27→ Common Stock (9,166 underlying) - Award
Common Stock
2025-02-28+4,583→ 30,962 total - Award
Common Stock
2025-02-28+5,000→ 26,379 total
Footnotes (4)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2026.
- [F2]Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.
- [F3]Represents the award of RSUs pursuant to the 2022 Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in two equal annual installments beginning February 28, 2026.
- [F4]This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Documents
Issuer
Karyopharm Therapeutics Inc.
CIK 0001503802
Entity typeother
Related Parties
1- filerCIK 0001942597
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 4:51 PM ET
- Size
- 11.5 KB